HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US Pandemic Relief Package Delivers OTC Industry Regulatory Wishes, Supplement Business Hopes

Executive Summary

It’s unlikely any industry stakeholder or FDA official expected a bill providing emergency economic relief to consumers, industries and health care services and facilities in response to a pandemic, including extensive support opportunities for small businesses, would be the vehicle that delivers on both of the industry’s congressional wishes. The supplement industry also looks for help in CARES Act.

You may also be interested in...

In Proposed Appropriation, Congress Tells FDA To Repurpose $7M For Cosmetic Regulation

Proposed budget agreement by House and Senate leaders comes four days before funding ends under the latest continuing resolution to keep the federal government open and a week before the White House plans to release its FY2025 budget request.

First US OTC Oral Contraceptive, Opill Marks Start Of Perrigo's Women’s Health ‘Mega-Brand’

“We do want to be a mega brand offering solutions across the women's sexual health journey. From the moment she enters into that category all the way through to post menopause, including fertility, we will develop out a mega brand,” says CEO Patrick Lockwood-Taylor.

Senate Democrats Push To Strike Insurers’ Option To Require Prescriptions For OTC Contraceptives

In letter to departments of Health and Human Services, Labor and Treasury, 47 of 48 Democrats and one of the three independents say allowing insurers the option “significantly reduces the advantages to consumers of an OTC product.”

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts